Transplant Immunosuppressive Drugs Market Size, Share, Opportunities, And Trends By Type (Induction Drugs, Maintenance Drugs), By Transplant type (Tissue Transplantation, Organ Transplantation), And By Geography – Forecast From 2025 To 2030

Transplant Immunosuppressive Drugs Market Size:

The Transplant Immunosuppressive Drugs Market is expected to grow from US$6.727 billion in 2025 to US$8.214 billion in 2030, at a CAGR of 4.08%.

The market in recent times has been witnessing advancements in transplantation techniques, including minimally invasive procedures and improved post-transplant care, which have increased the success rates of organ transplants. This has led to a higher demand for transplant immunosuppressive drugs to maintain the viability of transplanted organs and prevent rejection.

These drugs help protect patients against rejection of the transplanted foreign organ by their bodies. Moreover, the rising prevalence of chronic diseases such as cardiovascular disease, diabetes, cancer, and asthma is expected to increase the demand for organ transplants, further boosting the transplant immunosuppressive drugs market during the forecast period.

Significant advancements in pharmaceutical research and development have led to the introduction of new and improved transplant immunosuppressive drugs. These drugs are designed to enhance efficacy, minimize side effects, and improve patient outcomes, driving market growth. Moreover, the aging population is more prone to organ failure and chronic diseases, leading to a higher demand for organ transplantation. As the geriatric population grows globally, the transplant immunosuppressive drugs market is expected to expand further.

Transplant Immunosuppressive Drugs Market Growth Drivers:

• One of the primary reasons driving the market's growth is the increased number of organ transplant surgeries.

According to the health resources and services administration, 42,000+ transplants were performed in 2022, out of which 25,499 were for kidneys, 9,528 were for the liver, 108 were for the pancreas, 4,111 were for the heart, and 2,692 were for others.

Advancements in surgical techniques have improved the success rates of organ transplant surgeries, making them safer and more viable treatment options. Minimally invasive procedures, laparoscopic techniques, and innovative transplant approaches, such as living donor transplants and paired organ exchange programs, have expanded the pool of available organs and increased the number of surgeries performed. Furthermore, governments, healthcare organizations, and non-profit organizations have established dedicated programs and networks to promote and facilitate organ transplantation. These initiatives focus on creating efficient organ allocation systems, improving transplantation infrastructure, and increasing awareness about organ donation. For example, the United Network for Organ Sharing (UNOS) in the United States manages the organ transplant system and helps coordinate the allocation of organs.

• The organ transplantation segment will constitute a significant market share.

The transplant immunosuppressive drug market is segmented by transplant type into tissue and organ transplantation. According to the data collected by health resources and service administration on January 2023, there were 25,499 kidney transplants, whereas 9,528 liver transplants and heart and lung transplants were 4,111 and 2,692, respectively. Other transplants in the graph include allograft transplants like the face, hands, and abdominal wall.

The transplant immunosuppressive drugs market, by geography, is analyzed into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The development in tissue engineering and growing expenditure on healthcare, coupled with the increase in organ transplant surgeries, are driving the market growth for transplant immunosuppressive drugs in North America.

According to the data provided by the United Network for Organ Sharing (UNOS), in 2022, the total number of organ transplant procedures performed in the USA stood at 42,887, which signified an increase of 3.7% in comparison to the number of procedures performed in 2021. Moreover, as per the same source, 25,498 kidney transplant procedures were performed in 2022, representing a 3.4% increase over 2021. Such an increase in organ transplant procedures will positively impact the demand for transplant immunosuppressive drugs in the USA, accelerating market growth.

Market Segmentation:

• By Type
  • Induction Drugs
  • Maintenance Drugs
  • Anti-Rejection Drugs
• By Transplant Type
  • Tissue Transplantation
  • Organ Transplantation
  • Kidney Transplantation
  • Liver Transplantation
  • Heart Transplantation
  • Lung Transplantation
  • Pancreas Transplantation
  • Others
• By Drug Class
  • Calcineurin Inhibitors
  • mTOR Inhibitors
  • Antiproliferative Agents
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Corticosteroids
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Others
• By End-User
  • Hospitals
  • Transplant Centers
  • Specialty Clinics
  • Others

• By Geography
  
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE

5.1. Introduction

5.2. Induction Drugs

5.3. Maintenance Drugs

5.4. Anti-Rejection Drugs

6. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TRANSPLANT TYPE

6.1. Introduction

6.2. Tissue Transplantation

6.3. Organ Transplantation

6.4. Kidney Transplantation

6.5. Liver Transplantation

6.6. Heart Transplantation

6.7. Lung Transplantation

6.8. Pancreas Transplantation

6.9. Others

7. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY DRUG CLASS

7.1. Introduction

7.2. Calcineurin Inhibitors 

7.3. mTOR Inhibitors 

7.4. Antiproliferative Agents 

7.5. Monoclonal Antibodies 

7.6. Polyclonal Antibodies 

7.7. Corticosteroids 

7.8. Others

8. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.2. Oral 

8.3. Intravenous 

8.4. Others 

9. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY END-USER

9.1. Introduction

9.2. Hospitals

9.3. Transplant Centers

9.4. Specialty Clinics

9.5. Others

10. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY GEOGRAPHY

10.1. Introduction

10.2. North America

10.2.1. USA

10.2.2. Canada

10.2.3. Mexico

10.3. South America

10.3.1. Brazil

10.3.2. Argentina

10.3.3. Others

10.4. Europe

10.4.1. Germany

10.4.2. France

10.4.3. United Kingdom

10.4.4. Spain

10.4.5. Others

10.5. Middle East and Africa

10.5.1. Saudi Arabia

10.5.2. UAE

10.5.3. Others

10.6. Asia Pacific

10.6.1. China

10.6.2. India

10.6.3. Japan

10.6.4. South Korea

10.6.5. Indonesia

10.6.6. Thailand

10.6.7. Others

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

11.1. Major Players and Strategy Analysis

11.2. Market Share Analysis

11.3. Mergers, Acquisitions, Agreements, and Collaborations

11.4. Competitive Dashboard

12. COMPANY PROFILES

12.1. Astellas Pharma Inc.

12.2. Bristol-Myers Squibb Company

12.3. Sanofi Genzyme

12.4. Novartis Pharmaceuticals Corporation

12.5. Mylan N.V.

12.6. Hoffmann-La Roche Ltd

12.7. Accord Healthcare

12.8. Viatris Inc.

13. APPENDIX

13.1. Currency 

13.2. Assumptions

13.3. Base and Forecast Years Timeline

13.4. Key benefits for the stakeholders

13.5. Research Methodology 

13.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Sanofi Genzyme

Novartis Pharmaceuticals Corporation

Mylan N.V.

Hoffmann-La Roche Ltd

Accord Healthcare

Viatris Inc.